Skip to main content
OpenTrials
Completed

NCT Number: NCT05359523

Ultrasonographic Muscles and Fascia Measurement With Myofascial Pain Syndrome

Pathologies in the trapezius muscle and rhomboid muscle are important in the course and treatment of the disease in patients with myofascial pain syndrome.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Burcu Metin Ökmen, Nilufer, Bursa, Turkey (Türkiye)

Loading trial locations.

About this study

In this study, the role of the thickness of these muscles and the shift during movement in the activity and diagnosis of the disease in myofascial pain syndrome will be investigated.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18-65 years old
  • myofascial pain syndrome

Exclusion criteria

  • Cervical radiculopathy
  • Fibromyalgia
  • Shoulder joint disease,
  • Peripheral and central nervous system disease
  • Polyneuropathy,
  • Inflammatory rheumatic disease,
  • Malignancy

Treatment and study plan

Ultrasonographic measurements of the trapezius and rhomboid muscle and fascia

Device

B mode measurements Trapezius and rhomboid muscle thickness and fascial thickness measurement M mode measurements Abduction at 90 and 180 degrees Forward flexion at 90 and 180 degrees

fascia injection

Other

Under ultrasound guidance, a local anesthetic and steroid mixture will be injected into the fascia between the trapezius muscle and the rhomboid muscle.

Primary outcomes

  1. Trapezius muscle and rhomboid muscle thickness

    Time frame: 20 minute

    Trapezius and rhomboid muscle thickness and fascial thickness measurement will be made by ultrasonography at rest.

  2. fascial sliding

    Time frame: 20 minute

    Measurements of the amount of slip measured during the movement of the fascial structures during shoulder and arm movements.

    ultrasonography M-mode measurements Arm from the shoulder joint, cervical lateral flexion, cervical anterior flexion, shoulder elevation

Secondary outcomes

  1. VAS

    Time frame: 6 th month

    visual analog scale (VAS) :for pain. 0: no pain at all, 10: worst pain imaginable

  2. NPDS

    Time frame: 6th month

    Neck and Disability Scale (NPDS):

    The 20-item Neck and Disability Scale is scored on a 10 cm visual analog scale and ranges from 0 to 5 points. The test aims to measure the impact of neck pain on quality of life, functionality, and disability.

  3. SF-12

    Time frame: 6th month

    Short Form 12 (SF-12): The SF-12 form, which includes scales to assess physical (SF-12-PCS) and mental (SF-12-MCS) status, was created by taking 12 different items from 8 other titles of the SF-36, which is the extended version.

    Interpretation of Scores:

    Utilize the norm-based scoring system to interpret PCS and MCS scores, with a mean of 50 and a standard deviation of 10 in the general population.

    Scores above 50 indicate a better-than-average health-related quality of life, while scores below 50 suggest below-average health.

Sponsors and collaborators

Lead sponsor

Bursa Yuksek Ihtisas Training and Research Hospital

Other Gov

Registry information

Official study title

Investigation of the Diagnostic Effect of Ultrasonographic Measurement Values of Upper Back Muscles and Fascia in Patients With Myofascial Pain Syndrome

Important dates

Study start
2021
Primary completion
2024
Study completion
2024
First posted
May 4, 2022
Registry last updated
Jan 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.